Robert B. Rothermel Net Worth

The estimated Net Worth of Robert B Rothermel is at least $103 Thousand dollars as of 24 May 2019. Mr Rothermel owns over 6,500 units of Adamis Pharmaceuticals Corp stock worth over $102,795 and over the last 10 years he sold ADMP stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Rothermel ADMP stock SEC Form 4 insiders trading

Mr has made over 3 trades of the Adamis Pharmaceuticals Corp stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 6,500 units of ADMP stock worth $10,270 on 24 May 2019.

The largest trade he's ever made was buying 7,000 units of Adamis Pharmaceuticals Corp stock on 13 August 2015 worth over $23,310. On average, Mr trades about 1,727 units every 157 days since 2014. As of 24 May 2019 he still owns at least 133,500 units of Adamis Pharmaceuticals Corp stock.

You can see the complete history of Mr Rothermel stock trades at the bottom of the page.

Mr. Robert B. Rothermel biography

Robert B. Rothermel is the Consultant at Adamis Pharmaceuticals Corp.

How old is Mr Rothermel?

Mr Rothermel is 77, he's been the Consultant of Adamis Pharmaceuticals Corp since . There are 1 older and 12 younger executives at Adamis Pharmaceuticals Corp. The oldest executive at Adamis Pharmaceuticals Corp is Dr. Dennis J. Carlo, 78, who is the Pres, CEO & Director.

What's Mr Rothermel's mailing address?

Robert's mailing address filed with the SEC is C/O ADAMIS PHARMACEUTICALS CORPORATION, 11682 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130.

Insiders trading at Adamis Pharmaceuticals Corp

Over the last 14 years, insiders at Adamis Pharmaceuticals Corp have traded over $2,051,720 worth of Adamis Pharmaceuticals Corp stock and bought 87,550 units worth $188,843 . The most active insiders traders include Ahmed Shayan Fazlur Eses Ho..., Dennis J Phd Carlo, and David J. Marguglio. On average, Adamis Pharmaceuticals Corp executives and independent directors trade stock every 34 days with the average trade being worth of $12,919. The most recent stock trade was executed by Dennis J Phd Carlo on 25 May 2022, trading 250,000 units of ADMP stock currently worth $192,500.

What does Adamis Pharmaceuticals Corp do?

adamis pharmaceuticals corporation (nasdaq: admp) is a specialty biopharmaceuticals company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergies, oncology and immunology. its specialty pharmaceutical division currently has four products in its pipeline including the epinephrine injection pre-filled syringe (pfs) for use in the emergency treatment of anaphylaxis, apc-1000 and apc-5000 (dry powder inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (copd), and apc-3000, a hydrofluoroalkane (hfa) inhaled nasal steroid product for the treatment of allergic rhinitis. this division’s focus is to create low cost therapeutic alternatives to existing treatments in large markets. adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. within its biotechnology division, the company has four products under development include telob-vax, a

Complete history of Mr Rothermel stock trades at Adamis Pharmaceuticals Corp

Adamis Pharmaceuticals Corp executives and stock owners

Adamis Pharmaceuticals Corp executives and other stock owners filed with the SEC include:

• Dennis Carlo,
  President, Chief Executive Officer, Director
• Ronald Moss,
  Chief Medical Officer
• Robert Hopkins,
  Chief Financial Officer, Senior Vice President - Finance
• Dr. Dennis J. Carlo,
  Pres, CEO & Director
• David Marguglio,
  Senior Vice President, Chief Business Officer and Director
• Karen Daniels,
  Vice President - Operations
• Richard Williams,
  Independent Chairman of the Board, Consultant
• David J. Marguglio,
  Sr. VP, Chief Bus. Officer & Director
• Mark Flather,
  Director, Investor Relations and Corporate Communications
• Roshawn Blunt,
  Independent Director, Consultant
• Howard Birndorf,
  Independent Director, Consultant
• Robert B. Rothermel,
  Consultant
• Eddie Wabern Glover,
  Chief Exec. Officer of US Compounding Inc
• Jennifer C. Suski,
  Sr. Director of Marketing
• Karen K. Daniels,
  VP of Operations
• David C. Benedicto,
  Chief Financial Officer
• Thomas Moll,
  Vice President of Research
• William C Denby,
  Director
• Eddie Wabern Glover,
  CEO of US Compounding, Inc.
• Robert B Rothermel,
  Director
• Ahmed Shayan Fazlur Eses Ho...,
  
• Tina Susan Nova,
  Director
• Kenneth M Cohen,
  Director
• Craig A Johnson,
  Director
• Meera J. Desai,
  Director
• David C. Benedicto,
  Chief Financial Officer
• Vickie S Reed,
  Director
• Ebrahim Versi,
  CEO
• Jannine Versi,
  Director